ClinicalTrials.gg
RecruitingNCT07052253Updated Mar 16, 2026

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

A Phase 2 interventional study of TT-00420 (tinengotinib) and AK104 in Hepatocellular Carcinoma (HCC), sponsored by Akeso. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-16.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Carcinoma, Hepatocellular by Akeso — 5 open to participants now, 6 under way, 2 of them phase 3. Carcinoma, Hepatocellular · Akeso.

Planned enrollment
5th of 10
100 · median 80
Started
2025
with 1 other
Phase 2
6 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by Akeso, this one is the 5th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 2, and was the 10th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,062 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 10 studies in Carcinoma, Hepatocellular by Akeso are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 737 Carcinoma, Hepatocellular studies recruiting now, 382 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Hepatocellular by Akeso, or all of them as a file.
02

Study summary

An Open-label, Multicenter, Phase II Clinical Study of AK104/AK112 in Combination with TT-00420 Tablet in Patients with Advanced Hepatocellular Carcinoma(HCC).

03

Conditions studied

  • Hepatocellular Carcinoma (HCC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 and ≤ 75 years.
  2. or cytologically confirmed hepatocellular carcinoma, or meets the clinical diagnostic criteria for hepatocellular carcinoma.
  3. Barcelona Clinic Liver Cancer (BCLC) stage C; or stage B and assessed by the investigator as unsuitable for curative topical treatment.
  4. For cohorts A and B: No prior systemic anti-cancer treatment for hepatocellular carcinoma.
  5. At least one according to v1.1 criteria.
  6. liver function score ≤7. performance status of 0 or 1.
  7. Clinically controllable or infection.
  8. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. Previous or cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma, etc.
  2. Diagnosed with another within 3 years.
  3. History of hepatic encephalopathy.
  4. Presence of pericardial effusion; symptomatic pleural effusion requiring drainage or moderate to severe ascites uncontrolled by diuretics.
  5. Concurrent infection with and .
  6. Presence of central nervous system or meningeal metastases.
  7. Esophageal or gastric variceal bleeding within 6 months. Imaging (CT or MRI) shows extrahepatic metastasis invading major blood vessels or indistinct vascular boundaries, with high bleeding risk assessed by the researcher.
  8. Liver tumor volume exceeding 50% of total liver volume; portal vein main trunk tumor thrombus or tumor thrombus in contralateral main branch of the portal vein, or mesenteric vein tumor thrombus; presence of inferior vena cava thrombus or involvement of the heart.
  9. Received topical treatment for liver cancer, any systemic anti-tumor drugs, or other clinical trial drugs within 4 weeks prior to the first administration.
  10. Unable to swallow, or has severe gastrointestinal disease or gastrointestinal dysfunction. History of intestinal obstruction or intestinal perforation within 6 months.
  11. Uncontrolled hypertension, symptomatic heart failure, symptomatic or poorly controlled arrhythmia, myocarditis, cardiomyopathy, history of malignant arrhythmias.
  12. Participants with severe bleeding tendencies or coagulation disorders.
  13. Active pulmonary tuberculosis, active syphilis, or history of infection.
  14. Severe infection within 4 weeks prior to the first administration, or received systemic anti-infective treatment within 14 days.
  15. Other conditions with high medical risk or secondary tumor symptoms, which, in the judgment of the researcher, make the participant unsuitable for participation in the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Cohort 1(Safety Lead-In Phase)

    AK104 10mg/kg Q3W+TT-00420 10mg PO QD (n=3-6)

    Drug: TT-00420 (tinengotinib) · Drug: AK104

  • Experimental
    Cohort 2(Safety Lead-In Phase)

    AK112 20mg/kg Q3W + TT-00420 10mg PO QD(n=3-6)

    Drug: TT-00420 (tinengotinib) · Drug: AK112

  • Experimental
    Cohort A(Expansion Cohort Phase)

    AK104 10mg/kg Q3W + TT-00420 10mg PO QD(n=20-30)

    Drug: TT-00420 (tinengotinib) · Drug: AK104

  • Experimental
    Cohort B(Expansion Cohort Phase)

    AK112 20mg/kg Q3W + TT-00420 10mg PO QD(n=20-30)

    Drug: TT-00420 (tinengotinib) · Drug: AK112

  • Experimental
    Cohort C(Expansion Cohort Phase)

    TT-00420 10mg PO QD(n=20-30)

    Drug: TT-00420 (tinengotinib)

Interventions

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    assessed by investigator per RECIST v1.1

    Time frame: Up to 2 years

Secondary outcomes

  1. Progression-free survival (PFS)

    assessed by investigator per RECIST v1.1

    Time frame: up to 2 years

  2. Disease control rate(DCR)

    assessed by investigator per RECIST v1.1

    Time frame: Up to 2 years

  3. Duration of Response (DOR)

    assessed by investigator per RECIST v1.1

    Time frame: Up to 2 years

  4. Time to Response (TTR)

    assessed by investigator per RECIST v1.1

    Time frame: Up to 2 years

  5. Time to Progression (TTP)

    assessed by investigator per RECIST v1.1

    Time frame: Up to 2 years

  6. Overall Survival(OS)

    OS is defined as the time from randomization or first dosing to death due to any cause.

    Time frame: Up to 2 years

07

Study locations

1 of 1 sites recruiting
  • Union Hospital Tongji Medical College Huazhong University of Science And Technology
    Wuhan, China 430000, China
    Recruiting
    • Xiaoping Chen, M.D. · Contact
    • Xiaoping Chen, M.D. · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2027, 21 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's planned 21 months is below that.

Counting every sponsor, half of 428 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 4, 2025
StartActual
Jul 18, 2025
Primary completionEst.
May 10, 2027
CompletionEst.
Dec 31, 2027
Last update
Mar 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07052253
Lead sponsor
Akeso
Collaborators
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Jul 4, 2025
Start date
Jul 18, 2025
Primary completion
May 10, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Mar 16, 2026

Study contacts

Ting Liu, M.D.
Contact
clinicaltrials@akesobio.com
(0760)89873999

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tinengotinib

Start the discussion